SER

Serina Therapeutics, Inc. (SER) Economic Moat Analysis (2026)

Invetso Score: 1.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.0 (Weak)

SER’s available metrics do not evidence durable brand, regulatory, or IP-based pricing power, so it appears less protected than peers with identifiable intangible moats.

The absence of disclosed multi-year margin or return stability makes it difficult to support any peer-leading intangible advantage over competitors.

With no provided evidence of proprietary assets that improve retention or allow premium pricing, intangible assets look weak relative to stronger-moat peers.

Switching Costs

Score:

The negative TTM ROIC suggests customers are not locked in by high switching frictions that would preserve returns versus peers.

No provided evidence indicates workflow dependence, integration depth, or contractual lock-in that would make SER materially harder to replace than alternatives.

Compared with peers that benefit from embedded systems or recurring usage, SER’s switching-cost profile appears minimal and not durable.

Network Effects

Score:

The supplied data do not show user-to-user, data, or ecosystem feedback loops that would compound value over time versus peers.

Negative profitability and no visible scale-linked retention signal argue against a self-reinforcing network effect.

Relative to platform peers with clear participation flywheels, SER shows no evidence of network-driven moat strength.

Cost Advantage

Score:

TTM ROIC of -1.16% indicates SER is not converting capital into superior economics, which weakens any claim to a peer-level cost advantage.

The provided metrics do not show margin leadership, asset efficiency, or structurally lower unit costs versus peers.

Without evidence of scale purchasing, process superiority, or operating leverage, cost advantage appears weak and non-durable.

Efficient Scale

Score:

The data do not indicate that SER operates in a niche where a limited number of firms can profitably serve the market better than peers.

Negative returns and zero asset turnover do not support the presence of a protected scale position that deters entry.

Unlike peers with regulated or capacity-constrained markets, SER shows no evidence of efficient-scale protection.

Overall Score

Score:

SER shows no provided evidence of durable structural advantage across the five moat drivers, and the negative TTM ROIC plus lack of multi-year profitability data suggest weaker pricing power and retention than stronger peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Serina Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →